V
48
-2
MDT
50
-3
BLK
58
-2
T
68
2
M
23
6
K
63
3
IP
56
2
JCI
55
11
VFC
38
-2
FRT
46
-2
RL
65
5
CHD
54
-2
MAR
32
2
MAS
50
2
NRG
60
5
VMC
65
5
PCG
61
2
NKE
21
3
A
40
-4
CFG
62
-2
V
48
-2
MDT
50
-3
BLK
58
-2
T
68
2
M
23
6
K
63
3
IP
56
2
JCI
55
11
VFC
38
-2
FRT
46
-2
RL
65
5
CHD
54
-2
MAR
32
2
MAS
50
2
NRG
60
5
VMC
65
5
PCG
61
2
NKE
21
3
A
40
-4
CFG
62
-2
Financhill
Back

MoonLake Immunotherapeutics Stock Predictions

Marketing's AI Disruption Is Now Secure Your Stake Today!

DISCLOSURE: This is a paid advertisement for RAD Intel's Reg A offering. Please read the offering circular and related risks at invest.radintel.ai.
Sell
9

MLTX
MoonLake Immunotherapeutics

Last Price:
$38.46
Seasonality Move:
-12.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Meet the founder that's revolutionizing smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

MoonLake Immunotherapeutics Stock Forecast

  • Over the next 52 weeks, MoonLake Immunotherapeutics has on average historically risen by 57.6% based on the past 4 years of stock performance.
  • MoonLake Immunotherapeutics has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%
  • Is MoonLake Immunotherapeutics Stock Undervalued?
    The current MoonLake Immunotherapeutics [MLTX] share price is $36.35. The Score for MLTX is 9, which is 82% below its historic median score of 50, and infers higher risk than normal.
  • MLTX is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.

Will MoonLake Immunotherapeutics Stock Go Up Next Year?

  • Over the next 52 weeks, MoonLake Immunotherapeutics has on average historically risen by 57.6% based on the past 4 years of stock performance.

MoonLake Immunotherapeutics Stock Rating

Sell
9
MoonLake Immunotherapeutics (MLTX) is a Sell

Is MoonLake Immunotherapeutics overpriced?

  • MoonLake Immunotherapeutics has risen higher in 2 of those 4 years over the subsequent 52-week period, corresponding to a historical accuracy of 50%

MoonLake Immunotherapeutics Stock Price History

Is MLTX stock going to rise?

  • The current trend is relatively stagnant and MLTX is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Switzerland
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
moonlaketx.com

52-Week Data

52-Week High:
58.26
52-Week Low:
36.34

Prediction Charts

Market Cap:
2.3B
Price in USD:
36.35
Volume:
503.3K
Beta:
1.33

Technical Analysis

SMA50:
42.09
SMA100:
46.86
SMA200:
46.72
52-Wk Change:
-25.21%

Stock Predictions

  • Is MoonLake Immunotherapeutics stock public?
    Yes, MoonLake Immunotherapeutics is a publicly traded company.
  • What is the MoonLake Immunotherapeutics stock quote today?
    The MoonLake Immunotherapeutics stock price is 36.35 USD today.
  • How to buy MoonLake Immunotherapeutics stock online?
    You can buy MoonLake Immunotherapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-13 39.25 37.82 39.44 37.73
Mar-14 38.00 38.67 39.20 37.84
Mar-17 38.76 38.67 39.98 37.70
Mar-18 39.50 39.65 40.98 38.75
Mar-19 39.45 39.92 40.35 39.33
Mar-20 39.91 40.69 41.24 39.57
Mar-21 39.97 40.07 42.05 39.86
Mar-24 40.45 40.58 42.27 40.04
Mar-25 40.55 39.67 41.03 39.06
Mar-26 39.60 38.39 40.34 38.39
Mar-27 38.28 39.84 40.03 38.28
Mar-28 39.67 39.86 41.35 38.50
Mar-31 39.04 39.07 40.69 37.26
Apr-1 39.07 36.35 39.21 36.34

MoonLake Immunotherapeutics Earnings

MoonLake Immunotherapeutics Earnings Report: Per Share MoonLake Immunotherapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

MoonLake Immunotherapeutics Forecast Revenue Growth

MoonLake Immunotherapeutics Stock Analysis: Historical quarterly revenues per share for MoonLake Immunotherapeutics and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.32 per share, a decrease next quarter of $0.03 per share, a decrease this year of $1.43 per share, and a decrease next year of $0.47 per share.

* MoonLake Immunotherapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.